{"id":1811,"date":"2021-11-18T12:23:49","date_gmt":"2021-11-18T11:23:49","guid":{"rendered":"https:\/\/urologielandshut.de\/?page_id=1811"},"modified":"2022-12-15T10:08:54","modified_gmt":"2022-12-15T09:08:54","slug":"publikationen-priv-doz-dr-med-mark-thalgott","status":"publish","type":"page","link":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/","title":{"rendered":"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott"},"content":{"rendered":"<div id='av-layout-grid-1'  class='av-layout-grid-container av-a7tun7-22ab47cb1d414a02d51a540b278ddce0 entry-content-wrapper main_color av-flex-cells  avia-builder-el-0  el_before_av_hr  avia-builder-el-first   container_wrap fullsize'  >\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kw4v8m8r-b7fd6f94f89dbe8976517398b720aa10\">\n.flex_cell.av-kw4v8m8r-b7fd6f94f89dbe8976517398b720aa10{\nvertical-align:bottom;\nheight:500px;\nmin-height:500px;\npadding:0px 0px 0px 0px;\nbackground:url(https:\/\/www.urologielandshut.de\/wp-content\/uploads\/2022\/12\/urologie_unterschleissheim_thalgott_1.jpg) 0% 50% no-repeat scroll ;\n}\n<\/style>\n<div class='flex_cell av_one_half av-kw4v8m8r-b7fd6f94f89dbe8976517398b720aa10 no_margin  avia-builder-el-1  el_before_av_cell_one_half  avia-builder-el-first  av-zero-padding avia-full-stretch' ><div class='flex_cell_inner'><\/div><\/div>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-9klawj-2f131ac6b2db27cf6ed1c689302d734b\">\n.flex_cell.av-9klawj-2f131ac6b2db27cf6ed1c689302d734b{\nvertical-align:middle;\nheight:500px;\nmin-height:500px;\npadding:80px 80px 80px 80px;\nbackground-color:#22689e;\n}\n<\/style>\n<div class='flex_cell av_one_half av-9klawj-2f131ac6b2db27cf6ed1c689302d734b no_margin  avia-builder-el-2  el_after_av_cell_one_half  avia-builder-el-last ' ><div class='flex_cell_inner'>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kw4v91s1-2acda132ff79e635f479cd9a33b03ae8\">\n#top .av-special-heading.av-kw4v91s1-2acda132ff79e635f479cd9a33b03ae8{\npadding-bottom:25px;\ncolor:#ffffff;\nfont-size:34px;\n}\n.av-special-heading.av-kw4v91s1-2acda132ff79e635f479cd9a33b03ae8 .special-heading-inner-border{\nborder-color:#ffffff;\n}\n.av-special-heading.av-kw4v91s1-2acda132ff79e635f479cd9a33b03ae8 .av-subheading{\nfont-size:24px;\n}\n<\/style>\n<div  class='av-special-heading av-kw4v91s1-2acda132ff79e635f479cd9a33b03ae8 av-special-heading-h3 custom-color-heading blockquote modern-quote  avia-builder-el-3  avia-builder-el-no-sibling  av-inherit-size '><h3 class='av-special-heading-tag '  itemprop=\"headline\"  >Priv.-Doz. Dr. med. Mark Thalgott<\/h3><div class='av_custom_color av-subheading av-subheading_below '><p>Facharzt f\u00fcr Urologie<\/p>\n<\/div><div class='special-heading-border'><div class='special-heading-inner-border'><\/div><\/div><\/div>\n<\/div><\/div><\/div><div id='after_grid_row_1'  class='main_color av_default_container_wrap container_wrap fullsize'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-1811'><div class='entry-content-wrapper clearfix'>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-73n54j-2c98becdca1c4532d2d2dd30dfbf1142\">\n#top .hr.hr-invisible.av-73n54j-2c98becdca1c4532d2d2dd30dfbf1142{\nheight:30px;\n}\n<\/style>\n<div  class='hr av-73n54j-2c98becdca1c4532d2d2dd30dfbf1142 hr-invisible  avia-builder-el-4  el_after_av_layout_row  el_before_av_one_full  avia-builder-el-first  '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div><\/p>\n<div class='flex_column_table av-559hpf-483c4a9d7316901fb0435baac5721f09 sc-av_one_full av-equal-height-column-flextable'><div class='flex_column av-559hpf-483c4a9d7316901fb0435baac5721f09 av_one_full  avia-builder-el-5  el_after_av_hr  el_before_av_hr  first flex_column_table_cell av-equal-height-column av-align-top '   ><p>\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-kw4v9cgy-2e7f8f2839c1cfabf97555d3a27e6bcc\">\n#top .av-special-heading.av-kw4v9cgy-2e7f8f2839c1cfabf97555d3a27e6bcc{\npadding-bottom:10px;\n}\n.av-special-heading.av-kw4v9cgy-2e7f8f2839c1cfabf97555d3a27e6bcc .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-kw4v9cgy-2e7f8f2839c1cfabf97555d3a27e6bcc av-special-heading-h3 blockquote modern-quote  avia-builder-el-6  el_before_av_hr  avia-builder-el-first  '><h3 class='av-special-heading-tag '  itemprop=\"headline\"  >Publikationen<\/h3><div class='av-subheading av-subheading_below '><p>Priv.-Doz. Dr. med. Mark Thalgott<\/p>\n<\/div><div class='special-heading-border'><div class='special-heading-inner-border'><\/div><\/div><\/div><br \/>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3xlk77-f644306b30347f2b69ac422e1fecfcff\">\n#top .hr.hr-invisible.av-3xlk77-f644306b30347f2b69ac422e1fecfcff{\nheight:10px;\n}\n<\/style>\n<div  class='hr av-3xlk77-f644306b30347f2b69ac422e1fecfcff hr-invisible  avia-builder-el-7  el_after_av_heading  el_before_av_textblock  '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div><br \/>\n<section  class='av_textblock_section av-kw4vapjq-39fc47d3f455e1e5d28d51c853dc7ba6 '  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock '  itemprop=\"text\" ><p><strong>Buchbeitr\u00e4ge<\/strong><\/p>\n<p>Thalgott M, Lorch A, Schmidberger H, Schweyer St.: Seltene Hodentumoren, in Albers, Lorch, Gschwend: Uroonkologie, Schattauer Verlag, 1. Auflage, Stuttgart 2017<\/p>\n<p>Thalgott M, Gschwend JE: Kombination von mTOR-Inhibitoren mit anderen Substanzen pp. 81-94, in Th. Otto et al.: mTOR \u2013Inhibition ein neuer Wirkmechanismus in der Onkologie, UNI-MED Verlag AG, 1. Auflage, Bremen, 2009<\/p>\n<p><strong>\u00dcbersichtsarbeiten in Fachjournalen<\/strong><\/p>\n<p>Thalgott M, Tauber R, Gschwend JE, Hauner K: Therapie des fortgeschrittenen Urothelkarzinoms der Harnblase (Rev.) Onkologie heute, Juli 2017<\/p>\n<p>Thalgott M, Retz M, Straub M, Gschwend JE, Maisch P: Operative Therapie des Harnblasenkarzinoms (Rev.) Uro-News, Dezember 2016<\/p>\n<p>Thalgott M, Kurtz F, Gschwend JE, Straub M: Bildgebende Diagnostik bei Harnsteinen \u2013 aktueller Stand und neue Trends (Rev.) Urologe A. 2015 Jul;54(7):948-55.<\/p>\n<p>Thalgott M, Heck MM, Panthel K: Detektion zirkulierender Tumorzellen im peripheren Blut beim Prostatakarzinom (Rev.) Urologe A. 2014 Apr;53(4):509-13<\/p>\n<p>Tauber R, Horn T, Schmid S, Thalgott M, Haller B, Heck M, Gschwend JE, Maurer T: Die VAC-Therapie in der Pr\u00e4vention und Therapie der postoperativen inguinalen Lymphorrhoe (Rev.) KCI 2012<\/p>\n<p>Thalgott M, Gschwend JE, Retz M: Androgendeprivationstherapie des Prostatakarzinoms \u2013 Nebenwirkungen behandeln und Lebensqualit\u00e4t steigern (Rev.) Im Focus Onkologie, April 2011: 42-48<\/p>\n<p>Thalgott M, Gschwend JE, Retz M: Hormonablative Therapie des Prostatakarzinoms: Nebenwirkungen besser in den Griff bekommen (Rev.) Uro-News, M\u00e4rz 2011: 42-45<\/p>\n<p>Thalgott M, Gschwend JE, Retz M: Managing side effects of androgen deprivation in prostate cancer (Rev.) MMW Fortschr Med 2010 Oct 14;152(41):40-3<\/p>\n<p>Weckermann D, Thalgott M, Holl G, Wagner T, Harzmann R: Radioguided surgery in urological malignancies (Rev.) Indian J Urol., Jan 2008; 24 (1): 4-9<\/p>\n<p><strong>Fallberichte<\/strong><\/p>\n<p>Stock, Thalgott, Abeck: Italienische Bettbekanntschaften; Bayerisches \u00c4rzteblatt September (9) 2012, S. 429<\/p>\n<p><strong>Wissenschaftliche Publikationen in Fachjournalen<\/strong><\/p>\n<p>Thalgott M, D\u00fcwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE, Schwaiger M, Maurer T, Eiber M. One-stop shop whole-body 68Ga-PSMA-11 PET\/MRI compared to clinical Nomograms for preoperative T and N-Staging of High-Risk Prostate Cancer. J Nucl Med. 2018<\/p>\n<p>Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Schuster T, Autenrieth M, K\u00fcbler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. Clin Cancer Res. 2018 May 15;24(10):2342-2349<\/p>\n<p>Thalgott M, Kron M, Brath JM, Ankerst DP, Thompson IM, Gschwend JE, Herkommer K. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy. World J Urol. 2018 Feb;36(2):177-185<\/p>\n<p>Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017 Nov;72(5):828-834.<\/p>\n<p>Schwarzenb\u00f6ck SM, Knieling A, Souvatzoglou M, Kurth J, Steiger K, Eiber M, Esposito I, Retz M, K\u00fcbler H, Gschwend JE, Schwaiger M, Krause BJ, Thalgott M: [11C]Choline PET\/CT in therapy response assessment of a neoadjuvant therapy in locally advanced prostate cancer before radical prostatectomy. Oncotarget, 2016 Sep 27;7(39):63747-63757<\/p>\n<p>M\u00fccke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, Retz M, Gschwend JE, Thalgott M: Prevention of Bisphosphonate-Related Osteonecrosis of the Jaws in Patients with Prostate Cancer Treated with Zoledronic acid \u2013 a prospective study over 6 years. J Craniomaxillofac Surg. 2016 Oct;44(10):1689-1693.<\/p>\n<p>Schwarzenb\u00f6ck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, Treiber U, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Thalgott M*, Krause BJ*. Prospective evaluation of [11C]Choline PET\/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2105-2113.<\/p>\n<p>Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, H\u00f6ppner M, Retz M, Gschwend JE, Nawroth R. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Prostate. 2016 Sep;76(13):1160-8.<\/p>\n<p>Heck MM, Thaler MA, Schmid SC, Seitz AK, Tauber R, K\u00fcbler H, Maurer T, Thalgott M, Hatzichristodoulou G, H\u00f6ppner M, Nawroth R, Luppa PB, Gschwend JE, Retz M.: Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy. BJU Int. 2016 Mar 31<\/p>\n<p>Horn T, Zahel T, Adt N, Schmid SC, Heck MM, Thalgott MK, Hatzichristodoulou G, Haller B, Autenrieth M, K\u00fcbler HR, Gschwend JE, Holzapfel K, Maurer T: Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. Urol Int. 2016;96(1):51-6<\/p>\n<p>Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenb\u00f6ck SM, Krause BJ, Holm PS, Gschwend JE, Retz M, Nawroth R: CDK4\/6-inhibition controls proliferation of bladder cancer and transcription of RB1. J Urol. 2016 Mar;195(3):771-9<\/p>\n<p>Thalgott M, Rack B, Horn T, Heck MM, Eiber M, K\u00fcbler H, Retz M, Gschwend JE, Andergassen U, Nawroth R: Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy Anticancer Res. 2015 Oct; 35(10):5679-85.<\/p>\n<p>Hatzichristodoulou G, Wagenpfeil S, Weirich G, Autenrieth M, Maurer T, Thalgott M, Horn T, Heck MM, Herkommer K, Gschwend JE, K\u00fcbler H: Improved neuroprotection by ink-marked intraoperative frozen section monitoring of the prostate during nerve-sparing retropubic radical prostatectomy: a first prospective study reporting oncologic and functional results World J Urol. 2016 Feb;34(2):229-36.<\/p>\n<p>Thalgott M*, Rack B*, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, Retz M, Nawroth R: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. BMC Cancer. 2015 Jun 9;15:458.<\/p>\n<p>Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, K\u00fcbler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M: Prostate-specific Membrane Antigen\u2013radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol. 2015 Sep;68(3):530-4.<\/p>\n<p>Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, St\u00f6ckle M, B\u00f6gemann M, vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P: Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a German phase II trial (AUO trial AB 35\/09). Oncology. 2015 ;89(2):70-8.<\/p>\n<p>Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Gschwend JE, Retz M, Andergassen U*, Nawroth R*: Circulating tumor cells versus objective response assessment predicting survival in metastatic castration resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol. 2015 Aug;141(8):1457-64.<\/p>\n<p>Sathe A, Guerth F, Cronauer MV, Heck M, Thalgott M, Gschwend JE, Retz M, Nawroth R: Mutant PIK3CA controls DUSP1 dependent ERK 1\/2 activity to confer response to AKT target therapy. Br J Cancer. 2014 Nov 25;111(11):2103-13.<\/p>\n<p>Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, Autenrieth M, Herkommer K, Krause BJ, Gschwend JE, Treiber U, K\u00fcbler H: Phase II Study of Neoadjuvant Treatment with Docetaxel and Complete Androgen Blockade in Locally Advanced High Risk Prostate Cancer. J Hematol Oncol. 2014 Mar 5;7(1):20.<\/p>\n<p>Heck MM, Souvatzoglou M, Retz M, Nawroth R, K\u00fcbler H, Maurer T, Thalgott M, Gramer B, Weirich G, Rondak I, Rummeny EJ, Schwaiger M, Gschwend JE, Krause BJ, Eiber M: Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomgraphy\/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):694-701.<\/p>\n<p>Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, K\u00fcbler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R: Topography of Lymph Node Metastases in Prostate Cancer Patients Undergoing Radical Prostatectomy and Extended Lymphadenectomy: Results of a Combined Molecular and Histopathologic Mapping Study. Eur Urol. 2014 Aug;66(2):222-9.<\/p>\n<p>Thalgott M*, Rack B*, Maurer T, Souvatzoglou M, Eiber M, Kre\u00df V, Heck MM, Andergassen U, Nawroth R, Gschwend JE, Retz M: Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013 May;139(5):755-63.<\/p>\n<p>Tauber R, Schmid S, Horn T, Thalgott M, Heck M, Haller B, K\u00fcbler H, Autenrieth M, Retz M, Gschwend JE, Maurer T: Inguinal lymph node dissection: Epidermal vacuum therapy for prevention of wound complications. J Plast Reconstr Aesthet Surg. 2013 Mar;66(3):390-6.<\/p>\n<p>Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, K\u00fcbler H: Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int. 2012 Dec;110(11 Pt B):E635-40.<\/p>\n<p>Horn T*, Thalgott MK*, Maurer T, Hauner K, Schulz S, Fingerle A, Retz M, Gschwend JE, K\u00fcbler HR: Presurgical Treatment with Sunitinib for Renal Cell Carcinoma with a Level III\/IV Vena Cava Tumour Thrombus. Anticancer Research. 2012 May;32(5):1729-35.20<\/p>\n<p>Maurer T, Pournaras C, Aguilar-Pimentel JA, Thalgott M, Horn T, Heck M, Heit A, Kuebler H, Gschwend JE, Nawroth R: Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses. Urol Oncol. 2013 Oct;31(7):1395-401.<\/p>\n<p>Heck MM*, H\u00f6ppner M*, Horn T, Thalgott M, Gschwend JE, Retz M: Abiraterone- und Cabazitaxel-H\u00e4rtefallprogramm: erste klinische Erfahrungen bei Docetaxel-vorbehandelten kastrationsresistenten Prostatakarzinom-Patienten &#8211; Compassionate-use of abiraterone- and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients. Urologe A. 2012 Mar;51(3):390-7.<\/p>\n<p>Kupatt C, Horstkotte J, Vlastos G, Pfosser A, Lebherz C, Semisch M, Thalgott M, Mages J, Hoffmann R, Deten A, Beck H, Lamparter M, B\u00fcning H, Boekstegers P, Hatzopoulos A: Embryonic endothelial progenitor cells expressing a broad range of pro-angiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia. FASEB J. 2005 Sep; 19(11):1576-8.<\/p>\n<p>Pfosser A, Thalgott M, B\u00fcttner K, Brouet A, Feron O, Boekstegers P, Kupatt C: Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res. 2005 Feb 15;65(3):728-36<\/p>\n<p><strong>Ausgew\u00e4hlte Vortr\u00e4ge und Posterpr\u00e4sentationen<\/strong><\/p>\n<p>Schmid SC, Guerth F, Sathe A, Thalgott M, Heck MM, Maurer T, Gschwen JE, Retz M, Nawroth R. Autocrine Wnt signaling regulates cell proliferation in bladder cancer. EAU 2015<\/p>\n<p>M. Schrempf, T. Horn, M. Heck, T. Maurer, M. Thalgott, M. Autenrieth, J.E. Gschwend, H. K\u00fcbler: Initial experience of robotic assisted retroperitoneoscopic partial nephrectomy. ERUS 2014<\/p>\n<p>Thalgott M, Heck MM, Andergassen U, Eiber M, Souvatzoglou M, Horn T, Hatzichristodolou G, Gschwend JE, Retz M, Nawroth R: Circulating tumor cells versus objective response assessments predicting survival in metastatic castration resistant prostate cancer patients treated with docetaxel chemotherapy. DGU 2014<\/p>\n<p>Thalgott M, Kron M, Gschwend JE, Herkommer K: Prognostic value of family history for survival in prostate cancer patients treated with radical prostatectomy. DGU 2014<\/p>\n<p>Heck MM, Thalgott M, Schmid S, Seitz AK, Porst D, H\u00f6ppner M, Retz M, Gschwend JE, Nawroth R: Development and internal validation of an RNA-based marker model in whole blood as a prognostic biomarker for survival in metastatic castration-resistant prostate cancer patients. DGU 2014<\/p>\n<p>Schwarzenb\u00f6ck SM, Thalgott M, Kurth J, Souvatzoglou M, Treiber U, Eiber M, Retz M, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Krause BJ: C-11 Cholin PET\/CT zur Beurteilung des fr\u00fchen und sp\u00e4ten Therapieansprechens in der standardisierten Docetaxel Erstlinientherapie bei Patienten mit fortgeschrittenem kastrationsrefrakt\u00e4ren Prostatakarzinom. DGN 2014 (eingereicht)<\/p>\n<p>Hatzichristodoulou G, Heck M, Thalgott M, Wagenpfeil S, Herkommer K, K\u00fcbler H, Gschwend JE: Extended pelvic lymph node dissection during nerve-sparing radical prostatectomy and ist effect on erectile function recovery: comparison with standard lymph node dissection. ESSM 2014<\/p>\n<p>Hatzichristodoulou G, Weirich G, Wagenpfeil S, Autenrieth M, Maurer T, Thalgott M, Horn T, Heck M, Herkommer K, Gschwend JE, K\u00fcbler H: Verbesserte Neuroprotektion durch tuschemarkiertes intraoperatives Schnellschnitt-Monitoring der Prostata w\u00e4hrend der retropubischen radikalen Prostatektomie \u2013 Ergebnisse einer prospektiven Serie. Bay\u00d6 2014<\/p>\n<p>K\u00fcbler H, Maurer T, Horn T, Heck MM, Thalgott M, Gschwend JE, Autenrieth M: Roboter-assistierte retroperitoneoskopische Nierenteilresektion. DRUS 2013<\/p>\n<p>Maurer T, Berger H, Horn T, Heck MM, Thalgott M, Autenrieth M, Gschwend JE, K\u00fcbler H: Interventionelles Management bei arterieller Nachblutung nach roboterassistierter (Da VinciTM) Nierenteilresektion. DRUS 2013<\/p>\n<p>Schwarzenb\u00f6ck SM, Thalgott M, Souvatzoglou M, Eiber M, Retz M, Nawroth R, Rack B, Clemm C, Rummeny EJ, Gschwend JE, Schwaiger M, Krause BJ: Evaluation of choline PET\/CT in therapy response monitoring of standardized docetaxel first-line chemotherapy in patients with advanced hormone refractory prostate cancer. EANM 2013<\/p>\n<p>Thalgott M, Horn T, Maurer T, Heck M, Eiber M, Retz M, Autenrieth M, Herkommer K, Paul R, Gschwend JE, Treiber U, K\u00fcbler H: Neoadjuvante Hormonchemotherapie des lokal fortgeschrittenen Prostatakarzinoms mit Docetaxel und kompletter Androgenblockade &#8211; Ergebnisse einer Phase-II Studie. DGU 2013<\/p>\n<p>Hatzichristodoulou G, Weirich G, Wagenpfeil S, Herkommer K, Autenrieth M, Maurer T, Thalgott M, Horn T, Heck M, Gschwend J, K\u00fcbler H: Verbesserte Neuroprotektion durch tuschemarkierten intraoperativen Schnellschnitt der Prostata w\u00e4hrend der retropubischen radikalen Prostatektomie \u2013 Ergebnisse einer prospektiven Serie. DGU 2013<\/p>\n<p>Horn T, Zahel T, Adt N, Heck M, Thalgott M, Haller B, Gschwend J, Holzapfel K, Maurer T: Auswertung der konventionellen Computertomographie auf der Basis anatomischer Felder zur Diagnostik von Lymphknotenmetastasen beim Urothelkarzinom der Harnblase vor radikaler Zystektomie. DGU 2013<\/p>\n<p>Heck M, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, K\u00fcbler H, Maurer T, Thalgott M, Herkommer K, Gschwend J, Nawroth R: Topografie von Lymphknotenmetastasen im ausgedehnten Lymphadenektomiefeld bei Patienten mit lokal resektablem Prostatakarzinom: Ergebnisse einer molekularen und histopathologischen mapping-Studie. DGU 2013<\/p>\n<p>Heck M, Souvatzoglou M, Retz M, Nawroth R, K\u00fcbler H, Maurer T, Thalgott M, Gramer B. Weirich, G, Rummeny E, Schwaiger M, Gschwend J, Krause B, Eiber M: Prospektive Studie zum Vergleich von Computertomografie, Diffusion-gewichtetem mRT und [11c]cholin-PET-CT zur pr\u00e4operativen Detektion von Lymphknotenmetastasen bei Prostatakarzinom Patienten mit intermedi\u00e4rem und hohem Risiko. DGU 2013<\/p>\n<p>M Heck, Souvatzoglou M, Retz M, Nawroth R, K\u00fcbler H, Maurer T, Thalgott M, Gramer B, Weirich G, Rummeny BJ, Schwaiger M, Gschwend JE, Krause B, Eiber M: Prospektive Studie zum Vergleich von Computertomografie, diffusion-gewichtetem MRT und [11C]Cholin-PET-CT zur pr\u00e4operativen Detektion von Lymphknotenmetastasen bei Prostatakarzinom-Patienten mit intermedi\u00e4rem und hohem Risiko. Bay\u00d6 2013<\/p>\n<p>Heck M, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, K\u00fcbler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R: Topografie von Lymphknotenmetastasen im ausgedehnten Lymphadenektomiefeld bei Patienten mit lokal resektablem Prostatakarzinom: Ergebnisse einer molekularen und histopathologischen Mapping Studie Bay\u00d6 2013<\/p>\n<p>Thalgott M, Heck M, Eiber M, Sovatzoglou M, Maurer T, Kronester C, Andergassen U, Kehl V, Gschwend JE, Retz M, Nawroth R: Detektion zirkulierender Tumorzellen zum Therapiemonitoring des kastrationsrefrakt\u00e4ren Prostatakarzinoms (CRPC). Bay\u00d6 2013<\/p>\n<p>Thalgott M, Horn T, Maurer T, Heck M, Eiber M, Retz M, Autenrieth M, Herkommer K, Paul R, Gschwend JE, Treiber U, K\u00fcbler H: Update zur neoadjuvanten Hormonchemotherapie des lokal fortgeschrittenen Prostatakarzinoms mit Docetaxel und kompletter Androgenblockade \u2013 Ergebnisse einer Phase-II Studie. Bay\u00d6 2013<\/p>\n<p>M\u00fccke T, Hein J, Thalgott M, Gschwend JE, Wolff KD, Deppe H: Vermeidung von Bisphosphonat-assoziierten Knochennekrosen durch prophylaktische Ma\u00dfnahmen zur Verbesserung der Mundgesundheit bei Patienten mit metastasiertem Prostatakarzinom ID: 172 Jahreskongress der DGMKG 2013<\/p>\n<p>Tauber R, Schmid S, Heck M, Thalgott M, Autenrieth M, Gschwend JE, Maurer T: Vakuumtherapie bei ausgedehnter therapierefrakt\u00e4rer Lymphorrhoe und Wundheilungsst\u00f6rung nach inguinaler Lymphadenektomie &#8211; Pr\u00e4sentation einer Fallserie: KCI Symposium 2013<\/p>\n<p>Tauber R, Schmid S, Horn, Thalgott M, Heck M, Haller B, Gschwend JE, Maurer T: Epidermale Vakuumtherapie zur Pr\u00e4vention von Wundheilungsst\u00f6rungen nach inguinaler Lymphadenektomie. KCI Symposium 2013<\/p>\n<p>Hatzichristodoulou G, Weirich G, Wagenpfeil S, Herkommer K, Autenrieth M, Maurer T, Thalgott M, Horn T, Heck M, Gschwend JE, K\u00fcbler H: Ink marked intraoperative frozen section of the prostate during open radical prostatectomy \u2013 prospective analysis of diagnostic and therapeutic efficacy. EAU 2013<\/p>\n<p>Thalgott MK, Maurer T, Rack B, Souvatzoglou M, Eiber M, Heck M, Kre\u00df V, Andergassen U, R. Nawroth, Gschwend JE, Retz M: Detektion zirkulierender Tumorzellen (CTC) beim Prostatakarzinom &#8211; Prognostische Bedeutung und Assoziation zu klinischen Stagingparametern. DGU 2012<\/p>\n<p>Niegisch G, Retz M, Hartmann A, Thalgott M, Gschwend J, vom Dorp F, St\u00f6ckle M, B\u00f6gemann M, Balabanov S, Ohmann C, Albers P: AUO Studie AB 35\/09: Zweitlinientherapie des fortgeschritten Urothelkarzinoms mit RAD001 (Everolimus) und Paclitaxel. DGU 2012<\/p>\n<p>Heck M, Thalgott M, Retz M, Wolf P, Maurer T, Gschwend J, K\u00fcbler H: Prediction of favourable outcome and rational indication of docetaxel rechallenge in metastatic castration resistant prostate cancer. AUA 2012<\/p>\n<p>Thalgott MK, Maurer T, Heck M, Souvatzoglou M, Eiber M, Kre\u00df V, Rack B, Nawroth R, Gschwend JE, Retz M: Immunomagnetische Isolation zirkulierender Tumorzellen beim Prostatakarzinom &#8211; Prognostische Bedeutung und Assoziation zu klinischen Tumorcharakteristika. Bay\u00d6 2012<\/p>\n<p>Maurer T, Schmid S, Heck M, Thalgott M, Autenrieth M, Straub M, Gschwend JE, Tauber R: Vakuumtherapie bei ausgedehnter therapierefrakt\u00e4rer Lymphorrhoe und<br \/>\nWundheilungsst\u00f6rung nach inguinaler Lymphadenektomie &#8211; Pr\u00e4sentation einer Fallserie.<br \/>\nBay\u00d6 2012<\/p>\n<p>Heck MM, Thalgott MK, Retz M, Wolf P, Maurer T, Gschwend J, Kuebler H: Prediction of favorable outcome in a docetaxel rechallenge setting in metastatic castration-resistant prostate cancer. Genitourinary Cancers Symposium ASCO 2012<\/p>\n<p>Niegisch G, Retz M, Hartmann A, Thalgott M, Gschwend J, vom Dorp F, St\u00f6ckle M, B\u00f6gemann M, Balabanov S, Ohmann C, Albers P: Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35\/09). Genitourinary Cancer Symposium ASCO 2012<\/p>\n<p>Heck MM, Nawroth R, Bandur M, Souchay M, Vitzthum L, Weirich G, Schuster T, Thalgott M, Gschwend J, Retz M: Topography of molecularbiological micrometastases in lymph nodes of prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy. EAU 2012<\/p>\n<p>Niegisch G, Retz M, Hartmann A, Thalgott M, Gschwend J, vom Dorp F, St\u00f6ckle M, Ohlmann C, B\u00f6gemann M, Balabanov S, Ohmann C, Albers P: Second-line treatment of advanced urothelial cancer \u2013 safety of combinatory treatment with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35\/09). EAU 2012<\/p>\n<p>Heck M, Thalgott M, Retz M, Wolf P, Maurer T, Gschwend JE, K\u00fcbler H: Prediction of favourable outcome in metastatic castration-resistant prostate cancer patients treated with docetaxel rechallenge. DKG 2012<\/p>\n<p>Heck MM, Nawroth R, Souchay M, Vitzthum L, Bandur M, Weirich G, Schuster T, Thalgott M, Gschwend JE, Retz M: Detection and topography of micrometastases in lymphnodes of prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy using quantitative PCR. AUA 2011<\/p>\n<p>Heck MM, Nawroth R, Souchay M, Vitzthum L, Bandur M, Weirich G, Schuster T, Thalgott M, Gschwend JE, Retz M: Detection and topography of micrometastases in lymphnodes of prostate cancer patients treated with radical prostatectomy and extended lymphadenectomy using quantitative PCR. AUA 2011<\/p>\n<p>Nawroth R, Thalgott M, Maurer T, Gschwend JE, Retz M: Targeting the PI3K\/Akt\/mTOR pathway in bladder cancer: a rationale for multi target strategy. DGU 2011<\/p>\n<p>Niegisch G, Retz M, Hartmann A, Thalgott M, Gschwend J, vom Dorp F, St\u00f6ckle M, B\u00f6gemann M, Balabanov S, Albers P: AUO Studie AB 35\/09: Zweitlinientherapie des fortgeschritten Urothelkarzinoms mit RAD001 und Paclitaxel \u2013 erste Daten zur Sicherheit. DGU 2011<\/p>\n<p>Souvatzoglou M, Thalgott MK, Schwarzenboeck S, Eiber M, Kuebler H, Retz M, Gschwend JE, Schwaiger M, Krause BJ: [11C]Choline PET\/CT for therapy response assessment of neoadjuvant combined chemohormonal treatment in patients with high risk prostate cancer before radical prostatectomy. ISNM-Meeting USA 2011<\/p>\n<p>Thalgott M, Andergassen U, Kre\u00df V, Kronester C, Nawroth R, Rack B, Maurer T, Heck M, Horn T, Hauner K, Gschwend JE1, Retz M: Quantitative Detektion zirkulierender Tumorzellen (CTC) zum Monitoring der Chemotherapie beim Prostatakarzinom. DGU 2010<\/p>\n<p>Maurer T, Thalgott M, Aguilar-Pimentel JA, Horn T, Pournaras C, Gschwend JE, Nawroth R, Kuebler H: CpG-DNA mediated antigen shutteling enhances protein or peptide based immunotherapy in BL6\/C57 mice. DGU 2010<\/p>\n<p>Maurer T, Thalgott M, Aguilar-Pimentel JA, Horn T, Pournaras C, Gschwend JE, Nawroth R, Kuebler H: Enhancing protein or peptide based immunotherapy utilizing CpG-DNA mediated antigen shutteling. AUA 2010<\/p>\n<p>Thalgott MK, Andergassen U, Kronester C, Kre\u00df V, Nawroth R, Rack B, Maurer T, Heck M, Horn T, Gschwend JE, Retz M: Pilotstudie zum Therapiemonitoring des Prostatakarzinoms mit der quantitativen Detektion zirkulierender Tumorzellen (CTC). Bay\u00d6 2010<\/p>\n<p>Thalgott MK, Maurer T, Eiber M, Heck M, Horn T, Reimer B, Paul R, Herkommer K, Retz M, Treiber U, Gschwend JE, K\u00fcbler H: Neoadjuvante Hormonchemotherapie des lokal fortgeschrittenen Prostatakarzinoms mit Docetaxel und kompletter Androgenblockade. Bay\u00d6 2010<\/p>\n<p>K\u00fcbler H, Thalgott MK, Horn T, Beer AJ, Krause BJ, Gschwend JE: [11C]Cholin PET\/CT gesteuerte sekund\u00e4re Lymphadenektomie beim biochemischen Rezidiv nach radikaler Prostatektomie \u2013 Salvage oder Desperation Chirurgie? Bay\u00d6 2010<\/p>\n<p>Horn T, Thalgott M, Hauner K, Retz M, Gschwend JE, K\u00fcbler HR: Nierenzellkarzinome mit atrialem Tumorzapfen: Neoadjuvante Therapie mit Sunitinib. Bay\u00d6 2010<\/p>\n<p>Maurer T, Pournaras C, Aguilar-Pimentel JA, Thalgott M, Horn T, K\u00fcbler H, Gschwend JE, Nawroth R: PSA-Peptid und CpG-DNA Vakzinierung induziert spezifische zytotoxische T-Zell-Antwort im C57\/BL6 Mausmodell. Bay\u00d6 2010<\/p>\n<p>Thalgott MK, Treiber U, Maurer T, Heck M, Eiber M, Reimer B, Horn T, Paul R, Retz M, Gschwend JE, K\u00fcbler H: Neoadjuvante Hormonchemotherapie mit Docetaxel und kompletter Androgenblockade beim lokal fortgeschrittenen Prostatakarzinom. SWD 2010<\/p>\n<p>Thalgott MK, Andergassen U, Nawroth R, Rack B, Maurer T, Heck M, Horn T, Hauner K, Gschwend JE, Retz M: Quantitative Detektion zirkulierender Tumorzellen (CTC) beim Prostatakarzinom. SWD 2010<\/p>\n<p>Thalgott MK, Nawroth R, Andergassen U, Rack B, Maurer T, Heck M, Horn T, Herkommer K, Gschwend JE, Retz M: Pilot Trial for the Quantitative Detection of Circulating Tumor Cells in patients with prostate cancer. EAU 2010<\/p>\n<p>Thalgott MK, Treiber U, Maurer T, Heck M, Eiber M, Reimer B, Herkommer K, Paul R, Retz M, Gschwend JE, K\u00fcbler H: Neoadjuvant combination therapy of docetaxel and complete androgen deprivation for localized high risk prostate cancer before radical prostatectomy. EAU 2010<\/p>\n<p>K\u00fcbler H, Thalgott M, Horn T, Beer AJ, Krause BJ, Gschwend JE: [11C]Choline PET\/CT guided secondary lymph node dissection in recurrent prostate cancer after radical prostatectomy \u2013 salvage or desperation surgery? EAU 2010<\/p>\n<p>Thalgott MK, Nawroth R, Andergassen U, Rack B, Maurer T, Heck M, K\u00fcbler H, Herkommer K, Gschwend JE, Retz M: Detection of Circulating Tumor Cells (CTC) with the CellSearch\u00ae-System in patients with prostate cancer. Genitourinary Cancer Symposium ASCO 2010<\/p>\n<p>Thalgott MK, Nawroth R, Andergassen U, Rack B, Maurer T, Heck M, K\u00fcbler H, Herkommer K, Gschwend JE, Retz M: Detektion zirkulierender Tumorzellen (CTC) mit dem CellSearch\u00ae-System beim Prostatakarzinom. DKG 2010<\/p>\n<p>Maurer T, Thalgott M, Horn T, Aguilar-Pimentel JA, Gschwend JE, Nawroth R, K\u00fcbler H: Mechanismen und Strategien CpG-DNA basierter Vakzinierung \u2013 potentielle Anwendung beim Prostatakarzinom. AUF-Symposium 2009<\/p>\n<p>Thalgott MK, Nawroth R, Rack B, Schindlbeck G, Maurer T, Heck M, K\u00fcbler H, Gschwend JE, Retz M: Quantitative Detektion zirkulierender Tumorzellen (CTC) beim Prostatakarzinom. AUF-Symposium 2009<\/p>\n<p>Maurer T, Pournaras C, Aguilar-Pimentel JA, Heit A, K\u00fcbler H, Thalgott M, Gschwend J, Nawroth R: Zellul\u00e4re PSA-spezifische Immunantwort durch Peptid-Vakzinierung im C57\/BL6 Mausmodell. DGU 2009<\/p>\n<p>Thalgott MK, Nawroth R, Rack B, Schindlbeck G, Maurer T, Herkommer K, Gschwend JE, Retz M: Pilotstudie zur Detektion zirkulierender Tumorzellen (CTC) mit dem CellSearch\u00ae-System beim Prostatakarzinom. SWD 2009<\/p>\n<p>Thalgott MK, K\u00fcbler H, Eiber M, Maurer T, Gschwend JE, Retz M, Treiber U: Klinische Evaluation der Ansprechrate einer neoadjuvanten Kombinationstherapie aus Androgenblockade plus Docetaxel beim lokal fortgeschrittenen Prostatakarzinom (PCA). SWD 2009<\/p>\n<p>Thalgott MK, Richter O, Kron M, Gschwend JE, Herkommer K: Bedeutung des Lymphknotenstatus auf das progressfreie \u00dcberleben bei Patienten nach radikaler Prostatektomie. Bay\u00d6 2009<\/p>\n<p>Thalgott MK, Nawroth R, Rack B, Schindlbeck G, Maurer T, Herkommer K, Gschwend JE, Retz M: Pilotstudie zur Detektion zirkulierender Tumorzellen (CTC) mit dem CellSearch\u00ae-System beim Prostatakarzinom. Bay\u00d6 2009<\/p>\n<p>Maurer T, Aguilar-Pimental AJ, Pournaras C, Thalgott M, Heit A, Gschwend JE, Kuebler H, Nawroth R: Immunostimulatory CPG-DNA and PSA-Peptide Vaccination Elicites Profound Cytotoxic T Cell Responses. AUA 2009<\/p>\n<p><strong>Vortr\u00e4ge und Posterpr\u00e4sentationen im Rahmen der Dissertation<\/strong><\/p>\n<p>Pfosser A, Dietz M, Boettcher M, Fritz A, Dinges C, Thalgott M, Hatzopopoulus A, Boekstegers P, Kupatt Ch: \u201eHoming\u201c NF-kB-transfizierter embryonaler endothelialer Progenitorzellen (eEPCs) in einem xenogenen Modell chronischer Isch\u00e4mie. Clinical Research in Cardiology Suppl. 2006<\/p>\n<p>Pfosser A, Dietz M, Boettcher M, Dinges C, Fritz A, Thalgott M, Hatzopopoulus A, Boekstegers P, Kupatt Chr: Improved \u201eHoming\u201c of embryonic EPCs by p65-transfection in a xenotypic model of chronic ischemia. Journal of Vascular Research Suppl. 2006<\/p>\n<p>Pfosser A, Pfisterer I, Dietz M, Boettcher M, Dinges C, Fritz A, Thalgott M, Hatzopopoulus A, Boekstegers P, Kupatt Chr: Increased Recruitment of Embryonic EPCs in a Chronic Ischemic Hindlimb Model by Transient p65-Overexpression. Circulation Suppl. 2006<\/p>\n<p>Pfosser A, Thalgott M, B\u00fcttner K, Dietz M, B\u00f6ttcher M, Boekstegers P, Kupatt Chr: Mechanismen der Neovaskularisation durch regionale Hsp90 &#8211; cDNA \u00dcberexpression bei chronischer Isch\u00e4mie. Z Kardiol 94: Suppl. 1 2005<\/p>\n<p>Thalgott M, Pfosser A, Buettner K, Dietz M, Boettcher M, Feron O, Boekstegers P, Kupatt C: Induction of therapeutic angiogenesis and arteriogenesis by liposomal hsp90 transfection via nitric oxide in chronic hindlimb ischemia. J Vasc Res 2004, 41: p445<\/p>\n<p>Thalgott M, Pfosser A, Kupatt C: Therapeutische Neovaskularisierung durch Hsp90 Transfektion am chronisch isch\u00e4mischen Hinterlauf (Kaninchen). Z Kardiol 2004, 93: III\/106<\/p>\n<p>Pfosser A, Thalgott M, B\u00fcttner K, Boekstegers P, Kupatt C: Liposomal Hsp90-cDNA transfection initiates neovascularization in chronic ischemic hindlimbs: Evidence for a microvasculatory trigger mechanism. Circulation 2004, 110 Suppl: II-113<\/p>\n<p>Thalgott M, Pfosser A, Boekstegers P, Kupatt C: Hsp90 induces angiogensis \/ arteriogenesis in chronic hindlimb ischemia. J Vasc Res 2003, 40: p179<\/p>\n<p>Pfosser A, Lebherz C, Thalgott M, Raake P, Lamparter M, Boekstegers P, Hatzopoulos A, Kupatt C: Role of embryonal EPCs in chronic hindlimb ischemia of rabbits. Angiogenesis 2003, Vol.5 No.4 (2002): p317<\/p>\n<p>Wissenschaftliche Preise<\/p>\n<p>02.2010 Posterpreis der Deutschen Krebsgesellschaft: Thalgott MK, Nawroth R, Andergassen U, et al.: Detektion zirkulierender Tumorzellen (CTC) mit dem CellSearch\u00ae-System beim Prostatakarzinom<\/p>\n<p>06.2012 Posterpreis der Bayerischen Urologenvereinigung und der \u00d6sterreichischen Gesellschaft f\u00fcr Urologie und Andrologie: Thalgott MK, Maurer T, Heck M, et al.: Immunomagnetische Isolation zirkulierender Tumorzellen beim Prostatakarzinom &#8211; Prognostische Bedeutung und Assoziation zu klinischen Tumorcharakteristika<\/p>\n<p>06.2012 Posterpreis der Bayerischen Urologenvereinigung und der \u00d6sterreichischen Gesellschaft f\u00fcr Urologie und Andrologie: Maurer T, Schmid S, Heck M, Thalgott M, et al.: Vacuumtherapie bei Lymphorrhoe und Wundheilungsst\u00f6rung nach inguinaler Lymphadenektomie &#8211; Pr\u00e4sentation einer Fallserie<\/p>\n<p>06.2013 Posterpreis der Bayerischen Urologenvereinigung und der \u00d6sterreichischen Gesellschaft f\u00fcr Urologie und Andrologie: Thalgott M, Horn T, Maurer T, et al.: Update zur neoadjuvanten Hormonchemotherapie des lokal fortgeschrittenen Prostatakarzinoms mit Docetaxel und kompletter Androgenblockade \u2013 Ergebnisse einer Phase-II Studie<\/p>\n<p>06.2013 Werner &#8211; Staehler &#8211; Ged\u00e4chtnispreis, 3. Platz: Heck M, Souvatzoglou M, Retz M, Nawroth R, K\u00fcbler H, Maurer T, Thalgott M, et al.: Prospektive Studie zum Vergleich von Computertomografie, Diffusiongewichtetem MRT und [11C]Cholin-PET-CT zur pr\u00e4operativen Detektion von Lymphknotenmetastasen bei Prostatakarzinom-Patienten mit intermedi\u00e4rem und hohem Risiko<\/p>\n<\/div><\/section><\/p><\/div><\/div><!--close column table wrapper. Autoclose: 1 -->\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2ps9sj-54f79d41606209467ede44aeb57068f0\">\n#top .hr.hr-invisible.av-2ps9sj-54f79d41606209467ede44aeb57068f0{\nheight:30px;\n}\n<\/style>\n<div  class='hr av-2ps9sj-54f79d41606209467ede44aeb57068f0 hr-invisible  avia-builder-el-9  el_after_av_one_full  avia-builder-el-last  '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":1789,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/\" \/>\n<meta property=\"og:site_name\" content=\"Urologie Zentrum Landshut\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-15T09:08:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"26 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/\",\"url\":\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/\",\"name\":\"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut\",\"isPartOf\":{\"@id\":\"https:\/\/www.urologielandshut.de\/#website\"},\"datePublished\":\"2021-11-18T11:23:49+00:00\",\"dateModified\":\"2022-12-15T09:08:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.urologielandshut.de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c4rzte\",\"item\":\"https:\/\/www.urologielandshut.de\/aerzte\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Priv.-Doz. Dr. med. Mark Thalgott\",\"item\":\"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.urologielandshut.de\/#website\",\"url\":\"https:\/\/www.urologielandshut.de\/\",\"name\":\"Urologie Zentrum Landshut\",\"description\":\"Urologiezentrum Landshut\",\"publisher\":{\"@id\":\"https:\/\/www.urologielandshut.de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.urologielandshut.de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.urologielandshut.de\/#organization\",\"name\":\"Urologiezentrum Landshut\",\"url\":\"https:\/\/www.urologielandshut.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/www.urologielandshut.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.urologielandshut.de\/wp-content\/uploads\/2021\/11\/logo_urologie.png\",\"contentUrl\":\"https:\/\/www.urologielandshut.de\/wp-content\/uploads\/2021\/11\/logo_urologie.png\",\"width\":472,\"height\":259,\"caption\":\"Urologiezentrum Landshut\"},\"image\":{\"@id\":\"https:\/\/www.urologielandshut.de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/","og_locale":"de_DE","og_type":"article","og_title":"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut","og_url":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/","og_site_name":"Urologie Zentrum Landshut","article_modified_time":"2022-12-15T09:08:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"26 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/","url":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/","name":"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott - Urologie Zentrum Landshut","isPartOf":{"@id":"https:\/\/www.urologielandshut.de\/#website"},"datePublished":"2021-11-18T11:23:49+00:00","dateModified":"2022-12-15T09:08:54+00:00","breadcrumb":{"@id":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/publikationen-priv-doz-dr-med-mark-thalgott\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.urologielandshut.de\/"},{"@type":"ListItem","position":2,"name":"\u00c4rzte","item":"https:\/\/www.urologielandshut.de\/aerzte\/"},{"@type":"ListItem","position":3,"name":"Priv.-Doz. Dr. med. Mark Thalgott","item":"https:\/\/www.urologielandshut.de\/aerzte\/priv-doz-dr-med-mark-thalgott\/"},{"@type":"ListItem","position":4,"name":"Publikationen, Priv.-Doz. Dr. med. Mark Thalgott"}]},{"@type":"WebSite","@id":"https:\/\/www.urologielandshut.de\/#website","url":"https:\/\/www.urologielandshut.de\/","name":"Urologie Zentrum Landshut","description":"Urologiezentrum Landshut","publisher":{"@id":"https:\/\/www.urologielandshut.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.urologielandshut.de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.urologielandshut.de\/#organization","name":"Urologiezentrum Landshut","url":"https:\/\/www.urologielandshut.de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.urologielandshut.de\/#\/schema\/logo\/image\/","url":"https:\/\/www.urologielandshut.de\/wp-content\/uploads\/2021\/11\/logo_urologie.png","contentUrl":"https:\/\/www.urologielandshut.de\/wp-content\/uploads\/2021\/11\/logo_urologie.png","width":472,"height":259,"caption":"Urologiezentrum Landshut"},"image":{"@id":"https:\/\/www.urologielandshut.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/pages\/1811"}],"collection":[{"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/comments?post=1811"}],"version-history":[{"count":5,"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/pages\/1811\/revisions"}],"predecessor-version":[{"id":3219,"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/pages\/1811\/revisions\/3219"}],"up":[{"embeddable":true,"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/pages\/1789"}],"wp:attachment":[{"href":"https:\/\/www.urologielandshut.de\/wp-json\/wp\/v2\/media?parent=1811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}